BRPI0704179A - uso de agomelatina na obtenção de medicamentos pretendidos para o tratamento de leucomalacia periventricular - Google Patents

uso de agomelatina na obtenção de medicamentos pretendidos para o tratamento de leucomalacia periventricular

Info

Publication number
BRPI0704179A
BRPI0704179A BRPI0704179-9A BRPI0704179A BRPI0704179A BR PI0704179 A BRPI0704179 A BR PI0704179A BR PI0704179 A BRPI0704179 A BR PI0704179A BR PI0704179 A BRPI0704179 A BR PI0704179A
Authority
BR
Brazil
Prior art keywords
treatment
agomelatine
periventricular leukomalacia
drugs intended
obtain drugs
Prior art date
Application number
BRPI0704179-9A
Other languages
English (en)
Inventor
Michael Spedding
Elisabeth Mocaer
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229589&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0704179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of BRPI0704179A publication Critical patent/BRPI0704179A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE AGOMELATINA NA OBTENçãO DE MEDICAMENTOS PRETENDIDOS PARA O TRATAMENTO DE LEUCOMALACIA PERIVENTRICULAR. A presente invenção refere-se ao uso de agomelatina, ou N-¢2-(7-metóxi-1-naftil)etil!acetamida, na obtenção de medicamentos pretendidos para o tratamento de leucomalacia periventricular.
BRPI0704179-9A 2006-11-24 2007-11-23 uso de agomelatina na obtenção de medicamentos pretendidos para o tratamento de leucomalacia periventricular BRPI0704179A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610294A FR2908994B1 (fr) 2006-11-24 2006-11-24 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement de la leucomalacie periventriculaire

Publications (1)

Publication Number Publication Date
BRPI0704179A true BRPI0704179A (pt) 2008-07-08

Family

ID=38229589

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0704179-9A BRPI0704179A (pt) 2006-11-24 2007-11-23 uso de agomelatina na obtenção de medicamentos pretendidos para o tratamento de leucomalacia periventricular

Country Status (38)

Country Link
US (1) US20080125493A1 (pt)
EP (1) EP1927351B1 (pt)
JP (1) JP4870062B2 (pt)
KR (1) KR100976000B1 (pt)
CN (1) CN101185644B (pt)
AR (1) AR063895A1 (pt)
AT (1) ATE483458T1 (pt)
AU (1) AU2007234600B2 (pt)
BR (1) BRPI0704179A (pt)
CA (1) CA2610637C (pt)
CL (1) CL2007003395A1 (pt)
CY (1) CY1110875T1 (pt)
DE (1) DE602007009627D1 (pt)
DK (1) DK1927351T3 (pt)
EA (1) EA014067B1 (pt)
ES (1) ES2353128T3 (pt)
FR (1) FR2908994B1 (pt)
GE (1) GEP20094747B (pt)
HK (1) HK1118216A1 (pt)
HR (1) HRP20100680T1 (pt)
JO (1) JO2631B1 (pt)
MA (1) MA29522B1 (pt)
ME (1) ME01866B (pt)
MX (1) MX2007014004A (pt)
MY (1) MY145925A (pt)
NO (1) NO338598B1 (pt)
NZ (1) NZ563683A (pt)
PE (1) PE20081158A1 (pt)
PL (1) PL1927351T3 (pt)
PT (1) PT1927351E (pt)
RS (1) RS51494B (pt)
SG (1) SG143202A1 (pt)
SI (1) SI1927351T1 (pt)
TW (1) TW200829236A (pt)
UA (1) UA94043C2 (pt)
UY (1) UY30703A1 (pt)
WO (1) WO2008071869A2 (pt)
ZA (1) ZA200710102B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2810647A1 (en) * 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2810656B1 (en) 2013-06-06 2017-08-02 Zentiva, a.s. Agomelatine formulations comprising agomelatine in the form of co-crystals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2003011271A2 (en) * 2001-08-03 2003-02-13 Children's Medical Center Corporation Methods and compositions for modulating brain damage
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
MX2007014004A (es) 2009-02-16
FR2908994B1 (fr) 2009-04-03
KR20080047298A (ko) 2008-05-28
ATE483458T1 (de) 2010-10-15
CA2610637C (fr) 2011-04-19
AU2007234600A8 (en) 2010-12-02
AU2007234600A1 (en) 2008-06-12
FR2908994A1 (fr) 2008-05-30
DE602007009627D1 (de) 2010-11-18
AU2007234600B2 (en) 2012-05-17
WO2008071869A2 (fr) 2008-06-19
JO2631B1 (en) 2012-06-17
EP1927351A1 (fr) 2008-06-04
JP4870062B2 (ja) 2012-02-08
WO2008071869A3 (fr) 2008-08-14
EP1927351B1 (fr) 2010-10-06
RS51494B (en) 2011-04-30
ES2353128T3 (es) 2011-02-25
CN101185644B (zh) 2011-08-10
DK1927351T3 (da) 2011-01-10
NO20076002L (no) 2008-05-26
NZ563683A (en) 2009-04-30
JP2008133279A (ja) 2008-06-12
KR100976000B1 (ko) 2010-08-17
UY30703A1 (es) 2008-01-02
MA29522B1 (fr) 2008-06-02
ME01866B (me) 2011-04-30
SI1927351T1 (sl) 2010-12-31
HRP20100680T1 (hr) 2011-01-31
MY145925A (en) 2012-05-15
PL1927351T3 (pl) 2011-01-31
US20080125493A1 (en) 2008-05-29
AR063895A1 (es) 2009-02-25
SG143202A1 (en) 2008-06-27
CA2610637A1 (fr) 2008-05-24
PT1927351E (pt) 2010-10-27
TW200829236A (en) 2008-07-16
CY1110875T1 (el) 2015-06-10
UA94043C2 (ru) 2011-04-11
CL2007003395A1 (es) 2008-09-12
CN101185644A (zh) 2008-05-28
GEP20094747B (en) 2009-07-27
NO338598B1 (no) 2016-09-12
PE20081158A1 (es) 2008-10-04
HK1118216A1 (pt) 2009-02-06
EA014067B1 (ru) 2010-08-30
ZA200710102B (en) 2008-11-26
EA200702317A1 (ru) 2008-06-30

Similar Documents

Publication Publication Date Title
BRPI0701601A (pt) uso de agomelatina na obtenção de medicamentos previstos para o tratamento do dirtúrbio de ansiedade generalizada
BRPI0603762A (pt) uso de agomelatina para obtenção de medicamentos intencionados para o tratamento de distúrbios de sono em pacientes deprimidos
CL2007002446A1 (es) Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante.
BRPI0704179A (pt) uso de agomelatina na obtenção de medicamentos pretendidos para o tratamento de leucomalacia periventricular
BRPI0704453A2 (pt) uso de agomelatina para obtenção de medicamentos destinados ao tratamento da sìndrome de smith-magenis
CL2007003009A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del dolor, ansiedad y depresion.
UY29470A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares
EA201201123A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения обсессивно-компульсивного расстройства (окр)
CU20070070A7 (es) Composición farmacéutica de agomelatina
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
TH99000B (th) การใช้อะโกมีลาทีนในการทำให้มาถึงเวชภัณฑ์ที่มุ่งหมายสำหรับการรักษาเพอริเวนตริคูลาร์ ลิวโคมาลาเซีย
TH138902A (th) ผลึกร่วมแบบใหม่ของอะโกเมลาทีน กระบวนการในการเตรียมสารดังกล่าวและองค์ประกอบทางเภสัชกรรมที่ประกอบด้วยสารดังกล่าว
UA88322C2 (ru) Применение агомелатина как единственного активного агента в получении лекарственных средств, предназначенных для лечения генерализованного тревожного расстройства
SG131029A1 (en) New association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]